Recruiting
Phase 2

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

Sponsor:

Academic and Community Cancer Research United

Code:

NCT04626791

Conditions

Mantle Cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Acalabrutinib

Bortezomib

Cyclophosphamide

Cytarabine

Doxorubicin Hydrochloride

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information